DB-1303 is under clinical development by BioNTech and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DB-1303’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DB-1303 is under development for the treatment of advanced/unresectable, recurrent, or metastatic HER2-expressing malignant solid tumors, ovarian cancer, recurrent or metastatic endometrial carcinoma with HER2 overexpression, gastric, esophageal cancer, adenocarcinoma of the gastroesophageal junction, colorectal cancer, human epidermal growth factor receptor 2 positive breast cancer (her2 positive breast cancer), metastatic breast cancer, vaginal cancer, non-small cell lung cancer, adenocarcinoma . It is administered through intravenous route of administration. It is being developed based on DITAC platform. It acts by targeting Her2 expressing tumor cells and DNA topoisomerase I (Top I).
BioNTech is a biotechnology company that develops immunotherapies for cancer and infectious diseases. It is investigating mRNA therapeutics, engineered cell and gene therapies, antibodies and small molecule immunomodulators to treat advanced melanoma, solid tumors, non-small cell lung cancer (NSCLC), prostate, head and neck, ovarian, pancreatic and triple negative breast cancer. The company is also evaluating treatments for HIV, tuberculosis, malaria, hepatitis B, influenza, and COVID-19. BioNTech uses FixVac and iNeST technology platforms to discover and develop cancer immunotherapies targeting antigens and neoantigens. It works in partnership with Genentech Inc, Pfizer, Genmab AS and other biopharmaceutical companies to develop its pipeline products. BioNTech is headquartered in Mainz, Rhineland-Palatinate, Germany.
For a complete picture of DB-1303’s drug-specific PTSR and LoA scores, buy the report here.